Immunogenicity shown in Prevenar 13 studies

According to RTT News, in a Phase III safety and immunogenicity study, Prevenar 13 showed that the vaccine was immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar. This proved that there was a prevention of pneumonia and Streptococcus pneumoniae in children under five years old. Read the whole article here.

Share this article with your social network, just click below to share now!

Share |

Immunogenicity for Biotherapeutics 2010 Brochure Now Available!

Now in its 11th year, Immunogenicity for Biotherapeutics is THE longest running and THE largest event designed by and for the scientists who are driving progress and innovation in immunogenicity studies. The industry’s leading experts and scientists gather annually to discuss updates on emerging regulatory guidances, industry white papers, and exchange novel case studies and technology dedicated to drive forward the science, as well as, the discovery of solutions to the year’s top immunogenicity challenges.

Join us for THE immunogenicity event of the year to collaborate with the Elite Scientific Community Driving Innovation in Immunogenicity Screening and Characterization Strategies and Pushing Forward Regulatory Standardization and Global Best Practices.

We look forward to welcoming you April 26-28 in San Francisco. Download the brochure here. If you would like to join a community of others who focus on Immunogenicity, join the Immunogenicity for Biotherapeutics LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |